Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
## Dosage-Specific Reconstitution: 10mg, 12mg, 24mg & 30mg Vials Different vial sizes require different amounts of bacteriostatic water
Visual changes signal unsafe conditions for safe medication mixing
Fibrosis : Repeated injections may lead to the development of fibrous tissue within the penis, which can cause curvature or other complications
US$ 20.29
US$ 29.95
US$ 20.98
US$ 28.43
US$ 21.54
US$ 26.51
US$ 24.12
US$ 20.33
US$ 29.57
